Jean Holloway Sells 2,183 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 2,183 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $38.02, for a total value of $82,997.66. Following the completion of the transaction, the senior vice president owned 170,105 shares of the company’s stock, valued at approximately $6,467,392.10. This represents a 1.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Artivion Trading Down 0.5%

AORT opened at $38.41 on Thursday. The firm’s 50 day moving average is $41.42 and its 200-day moving average is $42.92. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $1.84 billion, a P/E ratio of 192.06 and a beta of 1.60.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion’s revenue for the quarter was up 19.2% compared to the same quarter last year. Analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on AORT. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Finally, Citizens Jmp raised their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Institutional Investors Weigh In On Artivion

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Partners Public Asset Management LLC acquired a new position in Artivion in the fourth quarter worth $39,401,000. Invesco Ltd. raised its holdings in shares of Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after purchasing an additional 748,119 shares during the period. Champlain Investment Partners LLC bought a new position in shares of Artivion in the 3rd quarter worth about $17,912,000. Goldman Sachs Group Inc. boosted its holdings in shares of Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after buying an additional 317,518 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of Artivion by 235.5% during the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock valued at $18,906,000 after buying an additional 313,446 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.